Notice: This company has been marked as potentially delisted and may not be actively trading. Anchiano Therapeutics (ANCN) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends ANCN vs. ALRN, BIVI, RFL, NBRV, VIRI, GANX, RLYB, QTTB, SCYX, and XLOShould you be buying Anchiano Therapeutics stock or one of its competitors? The main competitors of Anchiano Therapeutics include Aileron Therapeutics (ALRN), BioVie (BIVI), Rafael (RFL), Nabriva Therapeutics (NBRV), Virios Therapeutics (VIRI), Gain Therapeutics (GANX), Rallybio (RLYB), Q32 Bio (QTTB), SCYNEXIS (SCYX), and Xilio Therapeutics (XLO). These companies are all part of the "medical" sector. Anchiano Therapeutics vs. Aileron Therapeutics BioVie Rafael Nabriva Therapeutics Virios Therapeutics Gain Therapeutics Rallybio Q32 Bio SCYNEXIS Xilio Therapeutics Anchiano Therapeutics (NASDAQ:ANCN) and Aileron Therapeutics (NASDAQ:ALRN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, dividends, risk, valuation, earnings, community ranking and institutional ownership. Which has more risk & volatility, ANCN or ALRN? Anchiano Therapeutics has a beta of 0.93, meaning that its share price is 7% less volatile than the S&P 500. Comparatively, Aileron Therapeutics has a beta of 2.22, meaning that its share price is 122% more volatile than the S&P 500. Is ANCN or ALRN more profitable? Anchiano Therapeutics' return on equity of 36.08% beat Aileron Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Anchiano TherapeuticsN/A 36.08% 27.40% Aileron Therapeutics N/A -74.08%-27.93% Does the media favor ANCN or ALRN? In the previous week, Anchiano Therapeutics' average media sentiment score of 0.00 equaled Aileron Therapeutics'average media sentiment score. Company Overall Sentiment Anchiano Therapeutics Neutral Aileron Therapeutics Neutral Which has better earnings and valuation, ANCN or ALRN? Aileron Therapeutics is trading at a lower price-to-earnings ratio than Anchiano Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnchiano TherapeuticsN/AN/A-$27.12M-$3.46-0.49Aileron TherapeuticsN/AN/A-$15.73M-$3.12-0.56 Does the MarketBeat Community believe in ANCN or ALRN? Aileron Therapeutics received 155 more outperform votes than Anchiano Therapeutics when rated by MarketBeat users. Likewise, 66.98% of users gave Aileron Therapeutics an outperform vote while only 65.91% of users gave Anchiano Therapeutics an outperform vote. CompanyUnderperformOutperformAnchiano TherapeuticsOutperform Votes5865.91% Underperform Votes3034.09% Aileron TherapeuticsOutperform Votes21366.98% Underperform Votes10533.02% Do insiders and institutionals hold more shares of ANCN or ALRN? 9.1% of Anchiano Therapeutics shares are held by institutional investors. Comparatively, 90.9% of Aileron Therapeutics shares are held by institutional investors. 6.9% of Anchiano Therapeutics shares are held by insiders. Comparatively, 5.1% of Aileron Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Do analysts rate ANCN or ALRN? Aileron Therapeutics has a consensus target price of $19.00, indicating a potential upside of 985.71%. Given Aileron Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Aileron Therapeutics is more favorable than Anchiano Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anchiano Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Aileron Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 SummaryAileron Therapeutics beats Anchiano Therapeutics on 10 of the 14 factors compared between the two stocks. Ad Stansberry Research2025 could be “worse than the dot-com bust”, says man who predicted 2008 banking crisisDan is sharing his latest work with the public. Because what he's tracking right now, he says, is too serious to keep private.Click here to see Dan's full warning to the public. Get Anchiano Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ANCN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANCN vs. The Competition Export to ExcelMetricAnchiano TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.47M$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E Ratio11.2010.5990.1317.19Price / SalesN/A196.061,116.25117.05Price / CashN/A57.1643.1037.85Price / Book0.845.094.784.78Net Income-$27.12M$151.83M$120.31M$225.60M Anchiano Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANCNAnchiano TherapeuticsN/A$1.68+3.7%N/A+230.1%$12.47MN/A11.2016ALRNAileron Therapeutics3.0747 of 5 stars$2.14-5.3%$19.00+787.9%-41.9%$46.37MN/A-0.729Positive NewsBIVIBioVie1.1579 of 5 stars$2.61-1.1%$3.00+14.9%+53.2%$46.37MN/A-0.2310RFLRafael0.7384 of 5 stars$1.88-0.3%N/A+7.1%$46.26M$640,000.00-1.1313Gap UpNBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M-0.0739Analyst ForecastVIRIVirios TherapeuticsN/A$2.36-2.1%$3.00+27.1%+300.7%$45.45MN/A-8.745GANXGain Therapeutics2.6687 of 5 stars$1.65+1.2%$7.25+339.4%-37.6%$43.77M$50,000.00-1.4820RLYBRallybio2.6942 of 5 stars$1.04-3.7%$9.75+837.6%-63.6%$43.15MN/A-0.6740QTTBQ32 Bio2.8291 of 5 stars$3.47-6.2%$29.86+760.4%N/A$42.27M$-6,651,000.00-0.2439High Trading VolumeSCYXSCYNEXIS0.8192 of 5 stars$1.08-5.3%N/A-46.5%$40.99M$8.57M-1.5460Gap DownXLOXilio Therapeutics2.7966 of 5 stars$0.92-5.0%$4.00+334.8%+140.9%$40.44MN/A-0.5473News CoverageGap Up Related Companies and Tools Related Companies ALRN Alternatives BIVI Alternatives RFL Alternatives NBRV Alternatives VIRI Alternatives GANX Alternatives RLYB Alternatives QTTB Alternatives SCYX Alternatives XLO Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ANCN) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anchiano Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anchiano Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ANCN Stock Alerts